2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

Authors: Jørn Herrstedt, Rebecca Clark-Snow, Christina H. Ruhlmann, Alex Molassiotis, Ian Olver, Bernardo L. Rapoport, Matti Aapro, Kristopher Dennis, Paul J. Hesketh, Rudolph M. Navari, L. Schwartzberg, Mary Lou Affronti, Maria-Angeles Garcia-del-Barrio, Alexandre Chan, Luigi Celio, Ronald Chow, Mapi Fleury, Richard J. Gralla, Raffaele Giusti, Franziska Jahn, Hirotoshi Iihara, Ernesto Maranzano, Venkatraman Radhakrishnan, Mitsue Saito, Paula Sayegh, Snežana Bošnjak, Li Zhang, J. Lee, Vikas Ostwal, Teresa Smit, Ana Zilić, Karin Jordan, Florian Scotté - ESMO Open 2024 cited by 141

The 2015 MASCC–ESMO guideline for the prevention of ChT- and RINV was updated based on a literature search from 1 June 2015 through 31 January 2023. Thirty-four multidisciplinary experts reviewed the literature. The most important updates were as follows:1)Recommendation to use olanzapine as part of the prophylaxis for patients receiving HEC;2)Recommendation of a 1-day DEX schedule in patients treated with AC, carboplatin or other MEC;3)Suggestion to include an NK1-RA in the antiemetic regimen for women aged ≤50 years receiving oxaliplatin;4)Suggestion to use olanzapine for breakthrough CINV;5)For the first time providing suggestions for the use of some integrative and non-pharmacological therapies; and6)Recommending aprepitant or fosaprepitant as part of the weekly antiemetic regimen in women treated with fractionated radiotherapy and concomitant weekly cisplatin.